Skip to main content
In stock|Targeted Therapy

Dasatinib

Oncology TypeHematologic (Leukemia)
Drug Class / MechanismBCR-ABL Tyrosine Kinase Inhibitor
No Image
Description

Dasatinib is classified as a BCR-ABL Tyrosine Kinase Inhibitor, sourced for use within our Targeted Therapy portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryTargeted Therapy
Oncology TypeHematologic (Leukemia)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3